Primary neuroendocrine carcinoma of the breast A single Center experience and review of the literature

25.00

COD: 02_2017_04_2658 Categorie: ,

Paolo Locurto, Angelo Danilo Antona, Antonietta Grillo, Antonio Ciulla, Stefania Martorana, Calogero Cipolla, Giuseppa Graceffa, Salvatore Vieni

Ann. Ital. Chir., 2017 88, 2: 105-109

La mia nuova descrizione qui!

Price of a print issue: €25.00

Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because
only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December
2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection
and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according
TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel
of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and
Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and
Progesterone receptors were found. Ki-67 was higher than 40% in four patients. Adjuvant chemotherapy was administrated
in patients with Ki-67>10%; every patients were treated with radiotherapy and with hormonal therapy too.
Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size
of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.